Joint Pain Injections Market Size By Injection (Hyaluronic Acid Injections, Corticosteroid Injections, Platelet Rich Plasma Injections), By Joint (Knee, Shoulder & Elbow, Ankle & Hip), By End-use (Hospitals, Clinics), Industry Analysis Report, Regional Ou

Joint Pain Injections Market Size By Injection (Hyaluronic Acid Injections, Corticosteroid Injections, Platelet Rich Plasma Injections), By Joint (Knee, Shoulder & Elbow, Ankle & Hip), By End-use (Hospitals, Clinics), Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2023 - 2032

Joint Pain Injections Market trends are slated to be propelled by 2032 given the elevating demand for knee pain injections worldwide. Knee joint pain injections are deemed to be an ideal product to treat joint pain conditions. A recent evaluation of the Medicare sample database demonstrated that more than 1/3rd of patients with newly identified knee osteoarthritis were treated with at least one intra-articular corticosteroid injection.

Growing demand for joint pain injections for effective and quick treatment of joint inflammation and pain and soft tissue conditions would further strengthen the market outlook over 2023-2032.

Global expansion and product range diversification strategies by prominent market players are slated to have a positive impact on the industry growth. For example, Seikagu launched HyLink in Taiwan. The product is an intra-articular single injection viscosupplement for the treatment of knee osteoarthritis. It has been made of Seikagaku’s exceptional crosslinking technology.

The global joint pain injections industry has been bifurcated on the basis of injection type, joint type, end-use, and region.

Considering the injection type, the platelet rich plasma segment is predicted to amass considerable gains through 2032, attributable to its ability to provide optimum relief from pain and swelling and freedom of movement for a longer time. According to a study, the platelet rich plasma injections have depicted promising results in achieving pain reduction and improved function in patients suffering from OA. Besides, the injections also delay the need for knee replacement. Such factors would impel the segmental growth prospects in the ensuing years.

With regard to the joint type, ankle and hip segment would draw massive traction due to the rising incidence rate of ankle and hip arthritis. As per a recent survey, ankle osteoarthritis currently affects 1% of the global population, with an estimated frequency of 30 cases per 100,000 people. Moreover, advancements in joint pain injections that deliver ample benefits in treating ankle and hip joint pain and the launch of new products by prominent companies in the business sphere would potentially drive the market growth between 2023-2032.

Based on the end-use, clinics are estimated to gain major impetus in the global pain injections market fueled by the mounting preference of people for minimally invasive surgical procedures in these settings. Pivotal factors like the availability of a broad range of orthopedic procedures, incorporation of advanced technology for surgeries, and deliverance of high-quality services across clinics would add to the booming market curve. The segmental revenues are projected to surge beyond $2.5 billion by 2032.

Geographically, the sale of joint pain injections is estimated to gain momentum in Europe in the coming years on grounds of the growing healthcare expenditure, increasing geriatric population, and surging OA incidences in the region. The adoption of novel strategies by various central governments to promote access to orthopedic diseases treatments would complement the regional market growth over the review timeline.